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Focal scl£erosing glomerulonephritis (FSGN) is the leading 
cause of steroaid resistant nephrotic syndrome in childhood. 
Cytotoxic agenTts may induce remission but jeopardize future 
fertility. ~losporin (CYA) has reduced proteinuria at the cost 
of progressive: renal failure, probably contributed to by drug 
nephrotoxicit¥Y (1-2). We have used FK 506 to treat FSGN. A 
previously heaalthy 19 month old boy developed periorbital and 
peripheral edeema Noveaber 1988. Urinalysis revealed 4+ protein 
but was otherwwise unremarkable. Other laboratory data included: 
creatinine o.n mg/dl, BUN 16 mgt, albumin 1.8 gm% and serum 
cholesterol 4~ mgt. Antinuclear antibodies, C3, C4, hepatitis B 
screen, and anntistreptolysin-O (ASLO) titers were normal. 
Prednisone (L775 mgjday) was started but the proteinuria was not 
reduced duringg 7 months of therapy and the steroids were tapered 
to 35 mg/day. Increasing peripheral edema and ascites 
necessitated t:wo hospital admissions for intravenous diuretic 
therapy. A reenal biopsy after 9 months showed focal and 
segmental glomnerulosclerosis with moderate interstitial fibrosis. 
A course of C!yclophosphamide did not alter the proteinuria. 
At 30 mornths of age he was referred to us with grossly 
cushingoid fecatures and anasarca. He was receiving high dose 
loop diureticss and metolazone. Oral FK 506 (0.15 mg/kg/bid) was 
started and prrednisone was reduced to 5 mg/day, and after 4 
weeks, stoppecid. There was dramatic and progressive improvement 
clinically, arnd in the laboratory findings (Table 1). Diuretics 
were discontinued. He was experienced no side effects of FK 506 
to date, now afte~of weeks of therapy. 
A complete remission of FSGN occurred in this patient 
without a reduction in renal function, something not accomplished 
in previous reports of CyA induced remission of FSGN and other 
forms of steroid resistent nephrotic syndrome (1-4). We have 
recently reported that FK 506 in liver transplant recipients is 
more potent and less nephrotoxic than CyA (5). Our observations 
in this child as well as our recent successful treatment of CyA 
induced hemolytic uremic syndrome (6) suggests that FK 506 may be 
effective in a wide variety of renal and extra-renal immune 
mediated disorders. Cautious attempts will be in order to reduce 
the FK 506. There is no reason to assume that the present dose 
will be required for maintenance. 
The immediate response of a 41 year old male has been 
similar to that of the child, although it is too early to say 
more. The second patient with mesangial proliferative 
glomerulonephritis and steroid resistent nephrosis of 6 months 
duration (6-10 grams/day urine protein) was treated with 0.15 
mg/kg FK 506 starting on 13 February 1990 and with the 
discontinuance of 100 mg/day prednisone. Within the next 10 
days, urinary protein declined to 1485 mg, serum cholesterol fell 
from 360 to 240 mg/dr, and creatinine clearance remained the 
same. 
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